Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 12/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2521572 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2521573 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2549985 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL30208193 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL16081101 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2510991 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2512431 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL850195 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2510990 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL19821287 | 0.95 | BTN3A1 (0.47) | BTN3A1CYP3A4CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618926-B2 | Process for making phosphoramidate protected nucleoside compounds | MERCK SHARP & DOHME (US) | 2020-04-14 | — | — | US | disclosed |
| US-20180111954-A1 | PROCESS FOR MAKING PHOSPHORAMIDATE PROTECTED NUCLEOSIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180022774-A1 | PROCESS FOR THE PREPARATION OF SOFOSBUVIR | OPTIMUS DRUGS (P) LIMITED (IN) | 2018-01-25 | — | — | US | disclosed |
| WO-2017019581-A1 | PROCESS FOR MAKING PHOSPHORUS-CONTAINING NUCLEOSIDE PRODRUG COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2016160646-A1 | PROCESS FOR MAKING PHOSPHORAMIDATE PROTECTED NUCLEOSIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160271162-A1 | D-ALANINE PHOSPHORAMIDE PRONUCLEOTIDES OF 2'-METHYL 2'-FLURO GUANOSINE NUCLEOSIDE COMPOUNDS FOR THE TREATMENT OF HCV | IDENIX PHARMACUETICALS, LLC (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271162-A1 | D-ALANINE PHOSPHORAMIDE PRONUCLEOTIDES OF 2'-METHYL 2'-FLURO GUANOSINE NUCLEOSIDE COMPOUNDS FOR THE TREATMENT OF HCV | IDENIX PHARMACUETICALS, LLC (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2015066370-A1 | D-ALANINE PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-METHYL 2'-FLUORO GUANOSINE NUCLEOSIDE COMPOUNDS FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111954-A1 | PROCESS FOR MAKING PHOSPHORAMIDATE PROTECTED NUCLEOSIDE COMPOUNDS | PNP, NUDT1, RNGTT | BTN3A1 2834/4885CYP3A4 1804/4885CYP2C9 402/4885 |
| US-10618926-B2 | Process for making phosphoramidate protected nucleoside compounds | PNP, NUDT1, RNGTT | BTN3A1 2834/4885CYP3A4 1804/4885CYP2C9 402/4885 |
| US-20180022774-A1 | PROCESS FOR THE PREPARATION OF SOFOSBUVIR | SAMHD1, CPSF1, APOBEC3G | BTN3A1 4161/4885CYP3A4 5/4885CYP2C9 86/4885 |
| US-20160271162-A1 | D-ALANINE PHOSPHORAMIDE PRONUCLEOTIDES OF 2'-METHYL 2'-FLURO GUANOSINE NUCLEOSIDE COMPOUNDS FOR THE TREATMENT OF HCV | PNP, RNMT, ADAR | BTN3A1 4143/4885CYP3A4 3672/4885CYP2C9 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.